These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 7948298)

  • 41. Usefulness of intravenous thrombolytic therapy with pro-urokinase in acute myocardial infarction.
    Bode C; Schuler G; Schwarz F; Zimmermann R; Horn A; Kuebler W
    Am J Cardiol; 1987 Aug; 60(4):371. PubMed ID: 3113225
    [No Abstract]   [Full Text] [Related]  

  • 42. Thrombolytic agents for acute evolving myocardial infarction: comparative effects.
    Sherry S
    Ration Drug Ther; 1987 Jan; 21(1):1-9. PubMed ID: 3112866
    [No Abstract]   [Full Text] [Related]  

  • 43. New thrombolytic drugs in acute myocardial infarction: theoretical and practical considerations.
    Verstraete M
    Circulation; 1987 Aug; 76(2 Pt 2):II31-8. PubMed ID: 3111745
    [No Abstract]   [Full Text] [Related]  

  • 44. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
    Cannon CP; McCabe CH; Henry TD; Schweiger MJ; Gibson RS; Mueller HS; Becker RC; Kleiman NS; Haugland JM; Anderson JL
    J Am Coll Cardiol; 1994 Apr; 23(5):993-1003. PubMed ID: 8144799
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Thrombolytic therapy in acute myocardial infarction.
    Hampton JR
    Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():241-6. PubMed ID: 9211016
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction.
    Vanderschueren S; Dens J; Kerdsinchai P; Desmet W; Vrolix M; De Man F; Van den Heuvel P; Hermans L; Collen D; Van de Werf F
    Am Heart J; 1997 Aug; 134(2 Pt 1):213-9. PubMed ID: 9313600
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Newer thrombolytic agents.
    Verstraete M
    Ann Acad Med Singap; 1999 May; 28(3):424-33. PubMed ID: 10575530
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Thrombolytic therapy.
    Collen D; Stump DC; Gold HK
    Annu Rev Med; 1988; 39():405-23. PubMed ID: 3130773
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New directions in thrombolytic therapy.
    Toombs CF
    Curr Opin Pharmacol; 2001 Apr; 1(2):164-8. PubMed ID: 11714091
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Single-chain urokinase-type plasminogen activator: mechanism of action and thrombolytic properties.
    Lijnen HR; Stump DC; Collen DC
    Semin Thromb Hemost; 1987 Apr; 13(2):152-9. PubMed ID: 3114883
    [No Abstract]   [Full Text] [Related]  

  • 51. Hyperacute stroke therapy with tissue plasminogen activator.
    Alberts MJ
    Am J Cardiol; 1997 Aug; 80(4C):29D-34D; discussion 35D-39D. PubMed ID: 9284041
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Coronary thrombolysis in patients with acute myocardial infarction].
    Kambara H; Fudo T; Ono S
    Kokyu To Junkan; 1992 Jun; 40(6):537-47. PubMed ID: 1620990
    [No Abstract]   [Full Text] [Related]  

  • 53. Randomized, double-blinded multicenter study. Comparison of intracoronary single-chain urokinase-type plasminogen activator, pro-urokinase (GE-0943), and intracoronary urokinase in patients with acute myocardial infarction.
    Kambara H; Kawai C; Kajiwara N; Niitani H; Sasayama S; Kanmatsuse K; Kodama K; Sato H; Nobuyoshi M; Nakashima M
    Circulation; 1988 Oct; 78(4):899-905. PubMed ID: 3139325
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical profile of saruplase: angiographic findings.
    Meyer J
    Int J Clin Pract Suppl; 1998 Nov; 99():9-15. PubMed ID: 10344035
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Circadian variations of onset of acute myocardial infarction and efficacy of thrombolytic therapy.
    Kono T; Morita H; Nishina T; Fujita M; Hirota Y; Kawamura K; Fujiwara A
    J Am Coll Cardiol; 1996 Mar; 27(4):774-8. PubMed ID: 8613602
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Fibrinolytic agents--who benefits when?].
    Weichert W; Seifried E
    Ther Umsch; 1995 Oct; 52(10):652-60. PubMed ID: 7482376
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thrombolytic treatment in acute myocardial infarction.
    Acar J; Vahanian A; Michel PL; Slama M; Cormier B; Roger V
    Semin Thromb Hemost; 1987 Apr; 13(2):186-200. PubMed ID: 2957791
    [No Abstract]   [Full Text] [Related]  

  • 58. Another coronary reperfusion regimen.
    Simoons ML
    Lancet; 1995 Aug; 346(8971):324-5. PubMed ID: 7623525
    [No Abstract]   [Full Text] [Related]  

  • 59. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators.
    Metz BK; White HD; Granger CB; Simes RJ; Armstrong PW; Hirsh J; Fuster V; MacAulay CM; Califf RM; Topol EJ
    J Am Coll Cardiol; 1998 Jun; 31(7):1493-8. PubMed ID: 9626825
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Time course of left ventricular function and coronary patency after saruplase vs streptokinase in acute myocardial infarction. The PRIMI Trial Study Group.
    Schofer J; Lins M; Mathey DG; Sheehan FH
    Eur Heart J; 1993 Jul; 14(7):958-63. PubMed ID: 8375422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.